Media headlines about Genomic Health (NASDAQ:GHDX) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Genomic Health earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 44.4363246158034 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Genomic Health (GHDX) opened at $34.88 on Thursday. The company has a market capitalization of $1,203.92, a price-to-earnings ratio of -290.67 and a beta of 0.66. Genomic Health has a 12 month low of $26.37 and a 12 month high of $37.50.
Genomic Health (NASDAQ:GHDX) last announced its earnings results on Wednesday, November 8th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.04. Genomic Health had a negative return on equity of 1.79% and a negative net margin of 1.30%. sell-side analysts anticipate that Genomic Health will post -0.08 earnings per share for the current year.
In other Genomic Health news, insider Laura Leber sold 21,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $33.29, for a total value of $699,090.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider James J. Vaughn sold 1,379 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total value of $44,831.29. The disclosure for this sale can be found here. Insiders have sold 65,717 shares of company stock worth $2,158,232 in the last quarter. 46.20% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This report was originally published by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://baseballnewssource.com/markets/genomic-health-ghdx-earning-somewhat-positive-press-coverage-report-shows/1824520.html.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.